Effect of preservatives on IgG aggregation, complement-activating effect and hypotensive activity of horse polyvalent antivenom used in snakebite envenomation

Biologicals

Volumn 30, Issue 2, 2002, Pages 143-151

  García, Mildred ^a   Monge, María ^b   León, Guillermo ^b   Lizano, Sergio ^b   Segura, Eduardo ^b   Solano, Gabriela ^b   Rojas, Gustavo ^b   Gutiérrez, José María ^b  

^a Rodrigo Facio University City   (Costa Rica)

^b UNIVERSIDAD DE COSTA RICA   (Costa Rica)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISERUM; COMPLEMENT; DRUG PRESERVATIVE; HUMAN IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G HORSE LIQUID POLYVALENT ANTIVENOM; OCTANOIC ACID; PHENOL; SNAKE VENOM; SODIUM CHLORIDE; THIOMERSAL; UNCLASSIFIED DRUG;

ANGIONEUROTIC EDEMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BOLUS INJECTION; BRONCHOSPASM; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DILUTION; DIMERIZATION; DRUG COMPARISON; DRUG EFFECT; DRUG FORMULATION; DRUG INFUSION; DRUG STORAGE; DRUG USE; ENVENOMATION; FEMALE; FRACTIONATION; HEADACHE; HUMAN; HYPOTENSION; IMMUNOGLOBULIN AGGREGATE; IN VITRO STUDY; NAUSEA; NONHUMAN; PARAMETER; PRIORITY JOURNAL; PRURITUS; RAT; SERUM SICKNESS; SNAKEBITE; TEMPERATURE; TURBIDITY; URTICARIA; VOMITING;

EQUUS CABALLUS;

EID: 0036628393     PISSN: 10451056     EISSN: None     Source Type: Journal    
DOI: 10.1006/biol.2002.0329     Document Type: Article

References (37)

1. Bon C. Serum therapy was discovered 100 years ago. Bon C., Goyffon M. Envenomings and Their Treatment. 1996;3-9 Fondation Marcel Mérieux, Lyon.
2. Warrell D.A. The global problem of snake bite: its prevention and treatment. Gopalakrishnakone P., Tan C.K. Recent Advances in Toxinology Research, vol 1. 1992;121-153 National University of Singapore, Singapore.
3. Chippaux J.P. Snake-bites: appraisal of the global situation. Bull World Health Org. 76:1999;515-524.
4. Gutiérrez J.M., León G., Rojas G. Neutralization of local tissue damage induced by Bothrops asper (terciopelo) snake venom. Toxicon. 36:1998;1529-1538.
5. 2 and Fab of the antivenin. Toxicon. 36:1998;93-114.
6. Malasit P., Warrell D.A., Chanthavanich P. Prediction, prevention, and mechanism of early (anaphylactic) antivenom reactions in victims of snake bites. Br Med J. 292:1986;17-20.
7. Jurkovich G.J., Luterman A., McCullar K. Complications of Crotalidae antivenin therapy. J Trauma. 28:1988;1032-1037.
8. Cardoso J.L.C., Fan H.W., França F.O.S. Randomized comparative trial of three antivenoms in the treatment of envenoming by lance-headed vipers (Bothrops jararaca) in Sao Paulo, Brazil. Q J Med. 86:1993;315-325.
9. Otero-Patiño R., Cardoso J.L.C., Higashi H.G. A randomized, blinded, comparative trial of one pepsin-digested and two whole IgG antivenoms for Bothrops snake bites in Urabá, Colombia. Am J Trop Med Hyg. 58:1998;183-189.
10. Progress in the Characterization of Venoms and Standardization of Antivenoms. 1981;WHO Offset Publication 58, Geneva.
11. Warrell D.A. Clinical toxicology of snakebite in Asia. Meier J., White J. Handbook of Clinical Toxicology of Animal Venoms and Poisons. 1995;493-594 CRC Press, Florida.
12. 2 antivenoms. An example: new polyvalent European viper antivenom (equine). Bon C., Goyffon M. Envenomings and Their Treatments. 1996;161-172 Fondation Marcel Mérieux, Lyon.
13. Meyer W.P., Habib A.G., Onayade A.A. First clinical experiences with a new ovine Fab Echis ocellatus snake bite antivenom in Nigeria: randomized comparative trial with Institute Pasteur serum (IPSER) Africa antivenom. Am J Trop Med Hyg. 56:1997;291-300.
14. Moran N.F., Newman W.J., Theakston R.D.G. High incidence of early anaphylactoid reaction to SAIMR polyvalent snake antivenom. Trans R Soc Trop Med Hyg. 92:1998;69-70.
15. 2 equine antivenom in 223 African snake envenomations: a field trial in Cameroon. Trans R Soc Trop Med Hyg. 92:1998;657-662.
16. Ariaratnam C.A., Sjostrom L., Raziek Z. An open, randomized comparative trial of two antivenoms for the treatment of envenoming by Sri Lankan Russell's viper (Daboia russelii ruselii). Trans R Soc Trop Med Hyg. 95:2001;74-80.
17. Otero R., Gutiérrez J.M., Rojas G. A randomized blinded clinical trial of two antivenoms, prepared by caprylic acid or ammonium sulphate fractionation of IgG, in Bothrops and Porthidium snake bites in Colombia: correlation between safety and biochemical characteristics of antivenoms. Toxicon. 37:1999;895-908.
18. 2 polyvalent antivenoms: neutralization of systemic effects induced byBothrops asper venom, extravasation to muscle tissue, and potential for induction of adverse reactions. Toxicon. 39:2001;793-801.
19. Misbah S.A., Chapel H.M. Adverse effects of intravenous immunoglobulins. Drug Safety. 9:1993;254-262.
20. Sherer Y., Levy Y., Langevitz P. Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacology. 62:2001;133-137.
21. Barandun S., Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang. 51:1986;157-160.
22. Bleeker W.K., Agterberg J., Rigter G. An animal model for the detection of hypotensive side effects of immunoglobulin preparations. Vox Sang. 52:1987;281-290.
23. Bleeker W.K., Teeling J.L., Verhoeven A.J. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood. 95:2000;1856-1861.
24. Sutherland S.K. Serum reactions. An analysis of commercial antivenoms and the possible role of anticomplementary activity in de-novo reactions to antivenoms and antitoxins. Med J Australia. 1:1977;613-615.
25. Montero J., Trejos M., Lomonte B. Efecto del suero antiofídico sobre la actividad hemolítica del complemento humano (in vitro) y de conejo (in vivo). Rev Cost Cienc Méd. 10:1989;1-10.
26. Manual de Procedimientos. Producción y Pruebas de Control en la Preparación de Antisueros Diftérico, Tetánico, Botulínico, Antivenenos y de la Gangrena Gaseosa. 1977;Organización Panamericana de la Salud, Washington.
27. Raw I., Guidolin R., Higashi H.G. Antivenins in Brazil: Preparation. Tu A.T. Handbook of Natural Toxins, vol 5, Reptile Venoms and Toxins. 1991;557-581 Marcel Dekker, New York.
28. Angulo Y., Estrada R., Gutiérrez J.M. Clinical and laboratory alterations in horses during immunization with snake venoms for the production of polyvalent (Crotalinae) antivenom. Toxicon. 35:1997;81-90.
29. Rojas G., Jiménez J.M., Gutiérrez J.M. Caprylic acid fractionation of hyperimmune horse plasma: description of a rapid procedure for antivenom production. Toxicon. 32:1994;351-363.
30. Lacoste R.J., Venable S.H., Stone J.C. Modified 4-aminoantipyrine colorimetric method for phenols. Application to an acrylic monomer. Anal Chem. 31:1959;1246-1249.
31. Fries J., Getrost H. Organic reagents for trace analysis. 1977;E. Merck Darmstat, Germany.
32. Gutiérrez J.M. Clinical toxicology of snakebite in Central America. Meier J., White J. Handbook of Clinical Toxicology of Animal Venoms and Poisons. 1995;645-665 CRC Press, Florida.
33. Rodrigues-Silva R., Antunes G.F.C., Velarde D.T. Thermal stability studies of hyperimmune horse antivenoms. Toxicon. 37:1999;33-45.
34. Bleeker W.K., Agterberg J., Rigter G. Key role of macrophages in hypotensive side effects of immunoglobulin preparations. Studies in an animal model. Clin Exp Immunol. 77:1989;338-344.
35. Spycher M.O., Bolli R., Hodler G. Well-tolerated liquid intravenous immunoglobulin G preparations (IVIGs) have a low immunoglobulin G dimer (IgG-dimer) content. J Autoimmunity. 96:1999;96.
36. Harvey S.C. Antisépticos y desinfectantes; fungicidas; ectoparasiticidas. Gilman A.G., Goodman L.S., Rall T.W., Murad F. Las Bases Farmacológicas de la Terapéutica. 1988;914-933 Editorial Médica Panamericana, Buenos Aires.
37. 2 fragments. Toxicon. 32:1994;725-734.